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Abstract:
This is the first report on use of two visible spectrophotometric methods for the determination of
bupropion hydrochloride (BUPH) in pharmaceuticals and spiked human urine. Bupropion is a second-generation
antidepressant agent which is also used in the management of smoking cessation. The methods are based
on charge transfer complexation reaction of bupropion base (BUP) as n-electron donor with either p-chloranilic
acid (PCA) or 2,3-dichloro-5,6-dicyano-1,4-benzoquinone (DDQ) as π-acceptors to give highly colored radical
anion species. The colored products were quantified spectrophotometrically at 520 and 585 nm in PCA and
DDQ methods, respectively. Under the optimized experimental conditions, Beerûs law is obeyed over the
concentration ranges of 21.7-217 µg mL-1 and 5.65-67.8 µg mL-1 BUP for PCA and DDQ methods,
respectively. The molar absorptivity, Sandell sensitivity, detection and quantification limits are also reported.
The proposed methods were applied successfully to the determination of BUPH in pure form, commercial
tablets and spiked human urine with good accuracy and precision. Statistical comparison of the results was
performed with regard to accuracy and precision using Studentûs t-test and F-ratio at 95% confidence
level. There is no significant difference between the reference and proposed methods with regard to accuracy
and precision. Further, the validity of the methods was confirmed by recovery studies via standard addition
technique.
Keywords: Bupropion hydrochloride; Charge transfer complexation; Pharmaceutical; Spectrophotometry;
Spiked urine
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Introduction
Bupropion hydrochloride (BUPH), chemically known
as 1-(3-chlorophenyl)-2-[(1, 1-dimethylethyl) amino]-1-
propanone hydrochloride [1], is a water soluble salt of
an aminoketone [2], with a pKa of 7.9 [3] and it is also
known with the generic name of amfebutamone
hydrochloride. Bupropion is structurally related to
phenylethylamines, cathinone (a CNS stimulant from
leaves of Catha edulis) and to the anorectic drug
diethylpropion [4, 5]. Bupropion is a second-generation
antidepressant agent that is also used in the management
of smoking cessation [6]. Since its introduction in 1989,
the most extensively used technique for the quantitation
of BUPH is HPLC but, most of the procedures using
this technique are devoted to biological fluids like human
plasma [7, 8], plasma and serum [9] and dog plasma
[10]. Even such techniques as radioimmunoassay [11],
GC [12], LC [13, 14], LC/ESI/MS/MS [15], LC-MS [16]
and LC-MS/MS [17, 18] are mostly confined to biological
fluids including dog plasma [11], human plasma [12-14],
rat everted gut sacs [16], human plasma and urine [17]
and plasma of human, mouse and rat [18]. A limited
number of methods based on few techniques such as
non aqueous titration [19], HPLC [19-21], GLC [22]
and derivative UV spectrophotometry [23] are found in
the literature for the determination of BUPH in
pharmaceuticals.
To the best of our knowledge, no visible
spectrophotometric method has ever been reported for
the quantification of BUPH in pharmaceuticals. Visible
spectrophotometry, because of its simplicity and cost
effectiveness, sensitivity and selectivity, fair accuracy,
precision and easy access in most quality control
laboratories, has remained competitive in an area of
chromatographic techniques for pharmaceutical analysis.
This paper describes, for the first time, the
application of p-chloranilic acid (PCA) and 2,3-dichloro-
5,6-dicyano-1,4-benzoquinone (DDQ) as π-acceptors to
the spectrophotometric determination of BUPH based
on the interaction between these π-acceptors and the
secondary amine group of BUP as a good n-electron
donor to form charge-transfer complexes. These
π-acceptors have numerous applications as analytical
reagents and they have been used for the
spectrophotometric determination of many drugs in
pharmaceutical formulations [24-32]. The purpose of this
investigation was directed to develop simple, sensitive,
precise and inexpensive procedures for the quantification
of BUPH in pharmaceuticals and spiked human urine.
Materials and Methods
Instrument
A Systronics model 106 digital spectrophotometer
(Systronics, Ahmedabad, Gujarat, India) provided with
1-cm matched quartz cells was used for all absorbance
measurements.
Materials
Pharmaceutical grade bupropion hydrochloride (BUPH)
was received from GlaxoSmithKline Pharmaceuticals,
Mumbai, India. The following pharmaceutical preparations
were purchased from commercial sources in the local
market and subjected to analysis: Bupron-SR-150 (150
mg BUPH per tablet) from Sun Pharmaceutical Industries,
Jammu, India, and Ession-ER-150 (150 mg BUPH
per tablet) from Psycoremedies, Ludhiana, Punjab, India.
Urine was obtained from healthy volunteer (male, around
30 years old).
Reagents and chemicals
All the reagents and solvents used were of
analytical-reagent grade and distilled water was used
throughout the investigation.
1. PCA (Rolex Laboratory Reagent, Mumbai, India):
0.1% (w/v) solution in 1,4-dioxane (Merck, Mumbai, India)
was prepared and kept in the dark when not in use.
2. DDQ (Avra Synthesis Pvt. Ltd., Hyderabad, India):
0.2% (w/v) solution in acetonitrile (Merck, Mumbai, India),
was prepared afresh just before use.
3. Sodium hydroxide (Merck, Mumbai, India), 0.5
M aqueous solution.
Standard bupropion base solution
Fifty milligrams of pure bupropion hydrochloride
was dissolved in about 20 mL of water and the solution
was quantitatively transferred into a 125-mL separating
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funnel containing 10 mL of 0.5 M sodium hydroxide.
The base was extracted with 4 x 20 mL of chloroform.
The two phases were allowed to separate and the
chloroform layer was dried over anhydrous sodium
sulphate and transferred into a 100-mL volumetric flask.
The solvent was evaporated on a water bath and the
resulting yellow oil (bupropion base) was dissolved in
2.0 mL of methanol and the volume was then completed
to the mark with acetonitrile. The resulting solution (434
µg mL-1 in bupropion base) was used in method A and
diluted appropriately with acetonitrile to get a working
concentration of 113 µg mL-1 BUP for use in method B.
Recommended methods
Method A (using PCA)
Different aliquots (0.25, 0.5, 1.0,---2.5 mL) of a
standard BUP (434 µg mL-1) solution were accurately
transferred into a series of 5-mL volumetric flasks and
the total volume was adjusted to 2.5 mL by adding
adequate quantity of acetonitrile. To each flask was then
added 1.0 mL of 0.1% p-chloranilic acid, and the content
was mixed well and kept aside for 10 min. The mixture
was diluted to the volume with acetonitrile and the
absorbance was measured at 520 nm against a reagent
blank prepared simultaneously.
Method B (using DDQ)
Aliquots (0.25, 0.5, 1.0,---3.0 mL) of a standard
BUP (113 µg mL-1) solution were accurately transferred
into a series of 5-mL volumetric flasks and the total
volume was adjusted to 3.0 mL by adding adequate
quantity of acetonitrile to each flask. One milliliter of
0.2% DDQ solution was added to each flask and the
mixture was diluted to the volume with acetonitrile and
the absorbance of each solution was measured at 585
nm against a reagent blank.
Procedure for commercial tablets
Ten tablets each containing 150 mg of BUPH were
weighed and finely powdered. An accurately weighed
amount of the powder equivalent to 50.0 mg of BUPH
was dissolved in about 30 mL distilled water in a 50-mL
volumetric flask. The mixture was shaken for 10 min
and filtered using Whatman No. 42 filter paper in to a
125-mL separating funnel containing 10 mL of 0.5 M
sodium hydroxide. The base was extracted as described
under çStandard bupropion base solutioné. The base
solution (i.e. 434 µg mL-1 BUP) was assayed by the
method A, and diluted to get 113 µg mL-1 BUP before
applying the method B for the assay.
Procedure for spiked human urine sample
Urine (5 mL) was spiked with 50 mg of pure BUPH
and diluted to 25 mL with water and quantitatively
transferred into a 125-mL separating funnel containing
10 mL of 0.5 M sodium hydroxide. The solution was
mixed well and the base was then extracted as detailed
under çStandard bupropion base solutioné. The final
concentration of BUP in the resulting solution 434 µg
mL-1 was used in method A and was diluted appropriately
with acetonitrile to get a working concentration of 113
µg mL-1 BUP for use in method B.
Stoichiometric relationship
Jobûs method of continuous variations of equimolar
solutions was employed to establish the stoichiometry
of the colored products. The solutions equivalent to
1.81 x 10-3 and 2.17 x 10-3 M BUP were prepared.
Further, 1.81 x 10-3 M PCA and 2.17 x 10-3 M DDQ
solutions were prepared in 1, 4-dioxane and acetonitrile,
respectively. A series of solutions was prepared in which
the total volume of BUP and reagent was kept at 2 mL
in the total volume of 5 mL. The solutions were mixed in
various proportions; in method A, the volume was
completed to the mark after 10 min with both acetonitrile
and 1,4-dioxane keeping the ratio of the two solvents
as 1:1 in each flask while for method B, the volume was
completed to the mark with acetonitrile. The absorbance
of the resulting solutions was measured at the respective
wavelengths of maximum absorbance (λmax) against
the reagent blank under the same conditions.
Results and Discussion
Absorption spectra
The reaction of PCA as a π-acceptor with bupropion
base as n-electron donor results in the formation of an
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intense orange-red product which exhibits absorption
maxima at 520 nm (Figure 1) due to the formation of
the corresponding PCA radical anion. DDQ also acts as
a π-acceptor and the BUP-DDQ charge transfer complex
resulted in the formation of an intense reddish violet
color which exhibit three maxima at 585, 545 and 455
nm (Figure 2). These bands can be attributed to the
formation of DDQ radical anions arising from the complete
transfer of n-electrons from donor to acceptor moieties
in acetonitrile. The absorption band at 585 nm was
selected as analytical wavelength keeping in view
the sensitivity of the reaction product and blank
absorbance.
Reaction mechanism
The chemistry involved in the proposed methods
is based on the reaction of the basic nitrogen of
bupropion base as n-donor with the π-acceptors,
namely, PCA and DDQ to form charge transfer complexes
which subsequently dissociate into radical anions
depending on the polarity of the solvent used. In polar
solvents, such as acetonitrile, complete electron transfer
from the donor to the acceptor moiety takes place with
the formation of intensely colored radical anions [33],
according to the following equation:
DD DA A
Polar solvent
A
radical anioncharge transfer
complex
The dissociation of the (D → A) complex is promoted
by the high ionizing power of the acetonitrile.
The hydrochloride salts of amines do not react with
π-acceptors due to non-availability of non-bonding
electrons (n-electrons) on the nitrogen atom. To determine
amine-HCI, it is necessary to first neutralize the
hydrochloride and then extract the amine into a
non-aqueous solvent [28]. The neutralization of the
amine hydrochloride with sodium hydroxide and
extraction of HCl-free-amine into chloroform followed
by evaporating the chloroform was described by
Mostafa et al. [34]. Since bupropion hydrochloride as
such did not react with the π-acceptors, the salt was
converted to base followed by extraction, evaporation
and dissolving the residue in the solvents mentioned
under çStandard bupropion base solutioné. The tentative
reaction mechanisms for BUP-PCA and BUP-DDQ
complexes were proposed and illustrated in schemes
1 and 2, respectively.
Figure 1 Absorption spectra of charge transfer complex of BUP-PCA (108.5 µg mL-1 BUP): (a) BUP-PCA complex, (b) PCA in
1,4-dioxane
Ab
so
rb
an
ce
0.50
0.45 
0.40 
0.35 
0.30 
0.25 
0.20 
0.15 
0.10 
0.05 
0.00
Wavelength, nm
320 360 400 440 480 520 560 600 640
b
a
138 Thai J. Pharm. Sci. 34 (2010) 134-145
. HCl NaOH
Bupropion hydrochloride (BUPH) Bupropion base (BUP)
n-electron donor
+
O
O
Cl
HO Cl
OH
acceptor, PCA
C
Cl
O
CH
H
N
CH3
C
CH3
CH3
CH3
OO
Cl OH
ClHO
CT complexation
DA complex
FastF
ast
C
Cl
O
CH
H
N
CH3
C
CH3
CH3
CH3
+
O
O
Cl
HO Cl
OH
C
Cl
O
CH
H
N
CH3
C
CH3
CH3
CH3
+
O
O
Cl
HO Cl
OH
PCA
p-chloranilic acid radical anion
the measured species
Ace
tinit
rile-
dio
xan
e 
me
diu
m
C
Cl
O
CH
H
N
CH3
C
CH3
CH3
CH3
C
Cl
O
CH
H
N
CH3
C
CH3
CH3
CH3
C
Cl
O
CH
H
N
CH3
C
CH3
CH3
CH3
(BUP)
Scheme 1 The tentative reaction mechanism for BUP-PCA complex
The effect of different experimental variables
Effect of reagent concentration
The effect of the reagent concentration on the
intensity of the color developed at the selected
wavelengths was ascertained by adding different amounts
of the reagents PCA and DDQ to fixed concentrations
of 108.5 and 56.5 µg mL-1 BUP in method A and
method B, respectively. It was found that 1.0 mL of
0.1% PCA and 1.0 mL of 0.2% DDQ solutions were
sufficient for the production of maximum and reproducible
color intensity and the highest absorbance remained
unaffected by further addition of these reagents (Figure 3).
Effect of solvent
In order to select the suitable solvent for charge
transfer complex formation, the reaction of BUP with
PCA and DDQ was carried out in different solvents.
The acetonitrile-dioxane medium was found to be opt in
the case of PCA because PCA in 1,4-dioxane exists in
unionized form and acts as a π-acceptor like quinones
[27] and the acetonitrile showed super priority over
many solvents used such as chloroform, 2-propanol,
dichloroethane, methanol and ethanol. Acetonitrile was
found to be an ideal solvent in the case of DDQ, because
it afforded the maximum sensitivity when compared with
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Scheme 2 The tentative reaction mechanism for BUP-DDQ complex
all other solvents and it possesses the highest dielectric
constant of all solvents examined [35], a property which
is known to promote the dissociation of the original
charge-transfer complexes to the radical anions.
Effect of reaction time
The optimum reaction time was determined by
following the color development upon the addition of
reagent solution to the BUP solution at room temperature.
Complete color development was attained after 10 min
with PCA while the reaction with DDQ was instantaneous.
The absorbance of these radical anions remained
stable for at least 60 and 30 min for method A and
method B, respectively.
Molar ratio of the reaction
Jobûs continuous variations graph for the reaction
between BUP and PCA or DDQ (Figure 4) shows that
the interaction occurs on an equimolar basis via the
formation of a charge-transfer complexes 1:1 (BUP:
reagent). This finding was anticipated by the presence
of one basic or electron donating centre (-NH) in the
BUPH.
Method validation
Linearity
Under optimum experimental conditions for
determination of the drug under study, the absorbance
versus concentration plots were found to be linear over
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Figure 3 Effect of reagent concentrations on color development: (a) PCA (0.1%), (b) DDQ (0.2%)
Figure 2 Absorption spectra of charge transfer complex of BUP-DDQ (56.5 µg mL-1 BUP): (a) BUP-DDQ complex, (b) DDQ in
acetonitrile
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the concentration ranges stated in Table 1. The regression
parameters calculated from the calibration graphs
data, along with the standard deviations of the slope
(Sb) and the intercept (Sa) are presented in Table 1.
The linearity of the calibration graphs was demonstrated
by the high values of the correlation coefficient (r) and
the small values of the y-intercepts of the regression
equations. The molar absorptivity, Sandell sensitivity of
the methods A and B are also shown in Table 1.
Figure 4 Jobûs continuous-variation plot for: (a) [BUP] and [PCA] = 1.81 x 10-3 M and (b) [BUP] and [DDQ] = 2.17 x 10-3 M
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Table 1 Characteristic parameters for the charge transfer reaction of BUP with two π-acceptors
Parameter Method A Method B
λmax, nm 520 585
Colour stability, min 60 30
Beerûs law limits, µg mL-1 21.7-217 5.65-67.8
Molar absorptivity, L mol-1 cm-1 0.88 x 103 3.06 x 103
Sandell sensitivity*, µg cm-2 0.2732 0.0783
Limit of detection, µg mL-1 2.10 1.22
Limit of quantification, µg mL-1 6.38 3.71
Regression equation, Y**
Intercept, (a) 0.0209 0.0178
Slope, (b) 0.0034 0.0118
Correlation coefficient, (r) 0.9992 0.9997
Standard deviation of intercept (Sa) 0.00884 0.00554
Variance (Sa2) 7.81 x 10-5 3.07 x 10-5
±tSa / n 9.28 x 10-3 5.12 x 10-3
Standard deviation of slope (Sb) 0.00007 0.00014
±tSb/ n 7.34 x 10-5 1.30 x 10-4
*Limit of determination as the weight in µg per mL of solution, which corresponds to an absorbance of A = 0.001 measured in a cuvette of cross-sectional area
1.0 cm2 and l = 1.0 cm. Y** = a + bX, where Y is the absorbance and X concentration in µg/mL,  ±tSa / n  = confidence limit for intercept, ±tSb/ n  = confidence
limit for slope
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Sensitivity
Sensitivity of the methods can be determined,
through the limit of detection (LOD) and limit of
quantification (LOQ). The LOD for the proposed methods
were calculated using the following equation [36]
LOD  = 3.3 x σ (1)S
where σ is the standard deviation of replicate
determination values under the same conditions as for
the sample analysis in the absence of the analyte and
S is the sensitivity, namely the slope of the calibration
graph.
The LOQ, defined as [36]
LOQ  = 10 x σ (2)S
Based on the above equations, the limits of
detection and quantification were calculated and recorded
in Table 1.
Assay precision and accuracy
In order to determine the precision of the proposed
methods, solutions containing three different concentrations
of BUP were prepared and analyzed in seven replicates
and the analytical results are summarized in Table 2.
The low values of the relative standard deviation
(% R.S.D) and percentage relative error (% R.E) also
indicate the high precision and the good accuracy of
the proposed methods. RSD (%) and RE (%) values
were obtained within the same day to evaluate
repeatability (intra-day precision) and over five days to
evaluate intermediate precision (inter-day precision).
Selectivity
In order to evaluate the selectivity of the proposed
methods for the analysis of pharmaceutical formulations,
the effect of the presence of common excipients,
such as talc, starch, lactose, glucose, sodium alginate,
calcium gluconate and magnesium stearate was tested
for possible interference in the assay by placebo blank
and synthetic mixture analyses and no significant
interference was observed from these excipients.
Applications to analysis of pharmaceutical formulations
and spiked urine sample
The proposed methods were successfully applied
to the determination of BUPH in two representative
tablets Bupron-SR-150 and Ession-ER-150. The results
obtained are showed in Table 3 and were compared
with those obtained by the reference method [19] by
means of Studentûs t-and F-tests at 95% confidence
level. The reference method involved the visual titration
of the drug with acetous perchloric acid in non aqueous
medium using crystal violet indicator. In all cases, the
average results obtained by the proposed methods
and reference method were statistically identical, as the
difference between the average values had no significance
Table 2 Evaluation of intra-day and inter-day precision and accuracy
Method BUP taken Intra-day (n = 7) Inter-day (n = 5)
µg mL-1
BUP % REb % RSDc BUP % REb % RSDc
founda founda
µg mL-1 µg mL-1
Method A 86.80 88.10 1.50 1.42 88.30 1.73 2.04
130.20 131.61 1.08 1.60 131.80 1.23 1.83
173.60 177.80 2.42 0.69 177.30 2.13 1.16
Method B 22.60 22.79 0.84 2.10 22.92 1.42 1.38
33.90 34.16 0.77 1.32 34.22 0.94 2.00
45.20 45.95 1.66 1.79 46.13 2.06 2.41
a= Mean value of n determinations, b= Relative error (%), c= Relative standard deviation (%)
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at 95% confidence level with respect to accuracy and
precision. The proposed methods were also applied
to the determination of BUPH in spiked human urine
sample and the results are presented in Table 4.
Recovery study
To ascertain the validity of the proposed methods,
recovery experiment was performed via standard addition
technique. To a fixed and known amount of BUP in tablet
powder (pre-analyzed), pure BUP was added at three
concentration levels (50, 100 and 150% of the level present
in the tablet) and the total was measured by the proposed
methods. The determination with each concentration was
repeated three times and the results of this study
presented in Table 5 indicated that the various excipients
present in the formulations did not interfere in the assay.
Table 3 Results of assay of tablets and statistical evaluation
Commercial Found (% of nominal amount ± SD)*
tablets Reference method Proposed methods
Method A Method B
Bupron SR 150 98.14 ± 0.64 97.01 ± 1.24 97.43 ± 1.05
t = 1.90 t = 1.33
F = 3.75 F = 2.69
Ession ER 150 100.10 ± 0.73 98.62 ± 1.32 99.17 ± 0.98
t = 2.28 t = 1.72
F = 3.27 F = 1.80
*Mean value of five determinations,
Tabulated t-value at the 95% confidence level is 2.78; Tabulated F-value at the 95% confidence level is 6.39
Table 5 Results of recovery study using standard addition method
Method A Method B
 Formulation
 studied BUP Pure Total Pure BUP BUP Pure Total Pure BUP
taken, BUP found, recovered*, taken, BUP found, recovered*,
µg mL-1 added, µg mL-1 Percent ± SD µg mL-1 added, µg mL-1 Percent ± SD
µg mL-1 µg mL-1
Bupron SR 84.19 43.40 127.00 98.64 ± 2.97 22.02 11.30 33.38 100.53 ± 1.94
150 84.19 86.80 172.05 101.22 ± 2.21 22.02 22.60 44.33 98.72 ± 2.07
84.19 130.20 219.14 103.65 ± 1.54 22.02 33.90 54.72 96.46 ± 2.43
Ession ER 85.84 43.40 129.58 100.78 ± 1.86 22.41 11.30 33.44 97.60 ± 2.75
150 85.84 86.80 171.80 99.03 ± 2.05 22.41 22.60 45.51 102.21 ± 1.98
85.84 130.20 219.61 102.74 ± 1.47 22.41 33.90 56.89 101.71 ± 2.31
*Mean value of three determinations
Table 4 Determination of bupropion in spiked human urine sample
Method Spiked concentration Founda ± S.D. % Recovery ± RSD
(µg mL-1)
A 130.20 125.50 ± 3.35 96.39 ± 2.67
B 33.90 33.32 ± 1.11 98.29 ± 3.33
aMean value of five determinations; RSD is relative standard deviation
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Conclusion
This is the first report on the application of visible
spectrophotometry for the quantification of bupropion
in pharmaceuticals and human urine. The methods are
based on well-characterized charge-transfer complexation
reaction, and have the advantages of simplicity, speed,
accuracy and precision, and use of inexpensive
equipment compared to the reported HPLC and GC
methods. The DDQ method is more sensitive than
the PCA method as seen from the higher molar
absorptivity. UV spectrophotometry [23] method for
bupropion quantitation in pharmaceuticals has been
developed but this method has a narrow linear range
(10-30 µg mL-1) compared with the proposed methods.
Moreover, the proposed methods can be performed at
room temperature. The highlight of the proposed methods
is their ability to quantify bupropion in human urine
which in the past has been determined using very
expensive and sophisticated technique like LC-MS/MS.
Thus, the methods are useful for the quality control and
routine analysis of BUPH in pharmaceuticals since
there is no interference from the common excipients
that might be found in commercial formulations.
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